Tango Therapeutics, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
Tango Therapeutics, Inc. (TNGX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $0 as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2024-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $4.99M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 |
| 2024-06-30 | $4.99M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $12.95M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $32.16M 10-K · filed 2025-02-27 |
| 2023-09-30 | $41.79M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $87.88M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $108.06M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $123.00M 10-K · filed 2024-03-18 |
| 2022-09-30 | $33.81M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |